Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1855 results
August 2016
-
Story Discovery
Stifling danger signals in rheumatoid arthritis
Blocking an inflammatory pathway may offer a new way to treat autoimmune disease.
-
Press release
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
The Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and Harald von Boehmer for demonstrating that the ability of the immune system to discriminate "self" from "non-self" is… -
Story Access to Healthcare
Kenya confronts chronic diseases, building on progress against AIDS
While the country has made great strides in controlling AIDS and other infectious diseases, Kenyans are living longer and chronic diseases such as diabetes, heart disease and cancer are on the rise.
-
Press release
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Designation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer population and the potential of LEE011 (ribociclib) as an effective new treatment option Results… -
Press release
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…
July 2016
-
In The News
Novartis Access perspectives: How new business models can help fight chronic diseases
An editorial by Harald Nusser, Head Novartis Access & Malaria Initiative, in DEVEX -
Story From Our Labs
Reigniting a passion for science
How two years in a Novartis lab changed Johnny Castillo’s life.
-
Press release
Novartis réalise un 2ème trimestre solide, malgré l'impact sur le trimestre du générique de Gleevec aux US; nouvelles positives importantes de l'innovation renforcent les perspectives de croissance
Chiffre d'affaires net du T2 stable (0% tcc[1]), les produits de croissance[2] ayant compensé l'impact du générique de Gleevec Gilenya (USD 811 millions, +17% tcc) a continué de croître à un taux… -
Press release
Novartis erzielt im 2. Quartal solide Ergebnisse trotz US-Generikakonkurrenz für Gleevec im gesamten Quartal; wichtige positive Neuigkeiten zu Innovationen stärken zukünftige Wachstumsperspektiven
Der Nettoumsatz bleibt im zweiten Quartal unverändert (0% kWk[1]), da die Wachstumsprodukte[2] die Einbussen durch Generikakonkurrenz für Gleevec kompensieren Gilenya (USD 811 Millionen, +17%… -
Press release
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (… -
Featured News
Beyond the pill: precision medicine in practice
Learn how we are shifting from making the patient fit the treatment to making the treatment fit the patient.
-
Press release
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Presbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1] Dailies Total1® Multifocal contact lenses provide a seamless visual experience…